Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression

被引:0
|
作者
Bun'kova, K. M. [1 ]
机构
[1] IM Sechenov Med Acad, Moscow, Russia
来源
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2008年 / 108卷 / 03期
关键词
depression; psychopharmacotherapy; predictors; antidepressants;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The open comparative study of three antidepressants with different mechanisms of action - clomipramine, pirlindole and escitalopram - in the treatment of neurotic level depression (ICD-10 items F32-F34, F43) has been carried out. Ninety-one patients have been stratified into three groups included 31, 31 and 29 patients, respectively.. Duration of the study has been 12 weeks. Clomipramine, pirlindole and escitalopram have similar effect decreasing the total HAM-D score by more than 50% (in average 72%). Clomipramine appears to be more effective in the achievement of remission (63%) as compared to pirlindole (40%) and escitalopram (42%). The tolerability of pirlindole and escitalopram is higher than that of clomipramine and the authors recommend prescription of these drugs to patients with neurotic depression.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [21] Pirlindole in the Treatment of Depression A Meta-Analysis
    Macedo, Ana
    Leiria, Eva
    Filipe, Augusto
    CLINICAL DRUG INVESTIGATION, 2011, 31 (01) : 61 - 71
  • [22] Efficacy and tolerability of escitalopram in anxiety disorders: A review
    Pelissolo, A.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2008, 34 (04): : 400 - 408
  • [23] Efficacy and safety of escitalopram in treatment of severe depression in Chinese population
    Tianmei Si
    Gang Wang
    Fude Yang
    Yiru Fang
    Maosheng Fang
    Jijun Li
    Jicheng Dong
    Xinhua Shen
    Jianmin Zhuo
    Qing Rui
    Jinan Wang
    Hu Cuili
    Metabolic Brain Disease, 2017, 32 : 891 - 901
  • [24] Treatment of neurotic depression
    Raffaitin, F
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 1996, 22 : 43 - 45
  • [25] Escitalopram in the treatment of depression
    Duran, I.
    Gomez, R.
    Sanchez, P.
    Alvarez, T.
    Chinchilla, A.
    Vega, M.
    Cebollada, A.
    Manzanero, R.
    Regidor, A.
    Serrano, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S365 - S365
  • [26] Predicting the efficacy of escitalopram in the treatment of depression through urinary proteome
    Tang, Shuxuan
    Huan, Yuhang
    Yang, Jian
    Gao, Youhe
    INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, 2023, 484
  • [27] Efficacy and safety of escitalopram in treatment of severe depression in Chinese population
    Si, Tianmei
    Wang, Gang
    Yang, Fude
    Fang, Yiru
    Fang, Maosheng
    Li, Jijun
    Dong, Jicheng
    Shen, Xinhua
    Zhuo, Jianmin
    Rui, Qing
    Wang, Jinan
    Hu Cuili
    METABOLIC BRAIN DISEASE, 2017, 32 (03) : 891 - 901
  • [28] EFFICACY AND TOLERABILITY OF SUSTAINED-RELEASE CLOMIPRAMINE (ANAFRANIL SR) IN THE TREATMENT OF PHOBIAS - A COMPARISON WITH THE CONVENTIONAL FORMULATION OF CLOMIPRAMINE (ANAFRANIL)
    ALLSOPP, LF
    HUITSON, A
    DEERING, RB
    BRODIE, NH
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1985, 13 (04) : 203 - 208
  • [29] CYP2C19 INFLUENCE ON ESCITALOPRAM EFFICACY AND TOLERABILITY IN YOUTH WITH ANXIETY AND DEPRESSION
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S301 - S301
  • [30] Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naive patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns?
    Kaur, Harneet
    Sidana, Ajeet
    Singh, Thiyam Kiran
    JOURNAL OF MENTAL HEALTH AND HUMAN BEHAVIOUR, 2019, 24 (01) : 15 - 22